EFFICACY AND SAFETY OF LONAFARNIB FOR THE TREATMENT OF PROGERIA- A QUALITATIVE SYSTEMATIC REVIEW OF LITERATURE
Author(s)
Sharan N, Rathi H
Skyward Analytics Private Limited, Gurgaon, India
Presentation Documents
OBJECTIVES: Progeria is a rare, genetic, premature aging disease with no approved treatments currently. As lonafarnib is being investigated in Phase 2 clinical trials for treatment of progeria, we systematically reviewed the literature to identify the studies evaluating lonafarnib for the treatment of progeria. METHODS: PubMed, Cochrane, and Clinicaltrials.gov databases were searched on 18 October 2018 using keywords such as “progeria,” “Hutchinson-Gilford Syndrome," “HGPS,” and “premature aging syndrome”. Efficacy and safety data were extracted from studies selected after abstract and full-text screening. Quality assessment of included studies was performed using Downs and Black checklist. RESULTS: Eight publications were included, which reported data from three, Phase 2, single-arm trials of lonafarnib. Lonafarnib was administered as monotherapy in NCT00916747 and NCT00425607 and as triple-drug therapy with zoledronic acid and pravastatin in NCT00879034. In lonafarnib monotherapy trials, 36% of patients achieved successful rate of weight gain. Cardiovascular parameters improved in children treated with lonafarnib monotherapy. Although no additional cardiovascular benefit was observed with triple-drug therapy, significant improvements in absolute and height-adjusted areal bone mineral density (BMD) (p<0.001) and radial volumetric BMD at all sites (p<0.001–0.006) were observed. A successful rate of weight gain or decreased echodensity with triple-drug therapy was observed in 71% of patients. When compared with matched untreated cohort, survival analyses showed no significant difference in patients on triple-drug therapy; however, lonafarnib monotherapy (hazard ratio: 0.12; 95% confidence interval: 0.01─0.93; p=0.04) was associated with significantly decreased mortality. None of the patients withdrew from monotherapy or triple-drug therapy trial due to treatment-related toxicities. Adverse events (AEs) were consistent with previously reported AEs for lonafarnib. CONCLUSIONS: Lonafarnib was safe and well tolerated in the monotherapy and triple-drug therapy studies. Lonafarnib monotherapy improved cardiovascular parameters and survival of progeria patients. However, triple-drug therapy showed no additional cardiovascular benefit over monotherapy or survival benefit over matched untreated patients.
Conference/Value in Health Info
2019-05, ISPOR 2019, New Orleans, LA, USA
Value in Health, Volume 22, Issue S1 (2019 May)
Code
PRO4
Topic
Clinical Outcomes
Topic Subcategory
Clinical Outcomes Assessment
Disease
Rare and Orphan Diseases